Response to concerns over Cantillon et al. dopamine serotonin stabilizer RP5063 clinical trial's design, analyses and findings (SCHRES-D-17-00455) by Ahmed S Aboraya, MD, DrPh

Thank you for the opportunity to reply to Dr. Aboraya's letter, “Concerns Over Cantillon et al. Dopamine Serotonin Stabilizer RP5063 Clinical Trial's Design, Analyses and Findings.” (Aboraya 2017, Cantillon et al., 2017) After review of his comments and research into the issues raised, we stand by our data and conclusions and respond as follows:

Source: Schizophrenia Research - January 21, 2018 Category: Psychiatry Authors: Marc Cantillon, Laxminarayan Bhat Tags: Letter to the editor Source Type: research